X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs NATCO PHARMA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA NATCO PHARMA AUROBINDO PHARMA/
NATCO PHARMA
 
P/E (TTM) x 14.4 13.5 107.1% View Chart
P/BV x 2.9 2.8 103.7% View Chart
Dividend Yield % 0.4 1.6 27.1%  

Financials

 AUROBINDO PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
NATCO PHARMA
Mar-18
AUROBINDO PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs8091,080 74.9%   
Low Rs504671 75.1%   
Sales per share (Unadj.) Rs281.1592.1 47.5%  
Earnings per share (Unadj.) Rs41.4188.4 22.0%  
Cash flow per share (Unadj.) Rs50.9206.3 24.7%  
Dividends per share (Unadj.) Rs2.508.25 30.3%  
Dividend yield (eoy) %0.40.9 40.4%  
Book value per share (Unadj.) Rs199.4833.6 23.9%  
Shares outstanding (eoy) m585.8836.90 1,587.8%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.31.5 157.9%   
Avg P/E ratio x15.94.6 341.6%  
P/CF ratio (eoy) x12.94.2 304.1%  
Price / Book Value ratio x3.31.1 313.5%  
Dividend payout %6.04.4 138.1%   
Avg Mkt Cap Rs m384,63032,311 1,190.4%   
No. of employees `00017.34.8 358.8%   
Total wages/salary Rs m21,3083,256 654.4%   
Avg. sales/employee Rs Th9,500.74,522.5 210.1%   
Avg. wages/employee Rs Th1,229.4674.0 182.4%   
Avg. net profit/employee Rs Th1,397.91,439.0 97.1%   
INCOME DATA
Net Sales Rs m164,66621,848 753.7%  
Other income Rs m1,020404 252.4%   
Total revenues Rs m165,68622,252 744.6%   
Gross profit Rs m37,7189,284 406.3%  
Depreciation Rs m5,580662 842.9%   
Interest Rs m777154 504.7%   
Profit before tax Rs m32,3808,872 365.0%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1831,920 426.2%   
Profit after tax Rs m24,2296,952 348.5%  
Gross profit margin %22.942.5 53.9%  
Effective tax rate %25.321.6 116.8%   
Net profit margin %14.731.8 46.2%  
BALANCE SHEET DATA
Current assets Rs m121,87821,307 572.0%   
Current liabilities Rs m86,8065,920 1,466.3%   
Net working cap to sales %21.370.4 30.2%  
Current ratio x1.43.6 39.0%  
Inventory Days Days13073 177.3%  
Debtors Days Days68107 64.2%  
Net fixed assets Rs m81,03714,986 540.8%   
Share capital Rs m586369 158.8%   
"Free" reserves Rs m116,21830,353 382.9%   
Net worth Rs m116,80430,760 379.7%   
Long term debt Rs m4,5120-   
Total assets Rs m211,05237,151 568.1%  
Interest coverage x42.758.6 72.8%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.6 132.7%   
Return on assets %11.819.1 61.9%  
Return on equity %20.722.6 91.8%  
Return on capital %27.429.3 93.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72710,322 782.1%   
Fx outflow Rs m34,7002,978 1,165.0%   
Net fx Rs m46,0277,343 626.8%   
CASH FLOW
From Operations Rs m19,5484,636 421.7%  
From Investments Rs m-19,570-11,155 175.4%  
From Financial Activity Rs m8,6426,509 132.8%  
Net Cashflow Rs m8,922-18 -49,567.2%  

Share Holding

Indian Promoters % 54.1 52.0 104.0%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 8.0 7.8 101.4%  
FIIs % 27.7 16.6 166.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 26.0 39.2%  
Shareholders   69,601 25,395 274.1%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   IPCA LABS  NOVARTIS  PANACEA BIOTECH  PROCTER & GAMBLE HEALTH  SANOFI INDIA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum, Key Q1FY20 Results, and Top Stocks in Action Today(Pre-Open)

On Tuesday, share markets in India traded on a positive note throughout the day and ended above the 39,000-mark.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati(Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jul 16, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS